看片视频


Prokinetics in diabetic gastroparesis.
Authors Hejazi RA, McCallum RW, Sarosiek I
Submitted By Irene Sarosiek on 12/10/2012
Status Published
Journal Current gastroenterology reports
Year 2012
Date Published 8/1/2012
Volume : Pages 14 : 297 - 305
PubMed Reference
Abstract Within the last 50 years, diabetic gastroparesis has become a well recognized
complication of type 1 and type 2 diabetes. It is a syndrome characterized by
abnormal gastric function, resulting in delayed emptying of the stomach in the
absence of any evident mechanical obstruction, predominantly manifested by early
satiety, postprandial fullness, nausea, vomiting, and weight loss. The past five
years have shown significant advances in its pathophysiology and in new
diagnostic tests. Prokinetic medications remain the therapeutic focus for
improving clinical symptoms of gastroparesis through enhanced gastric emptying.
This article summarizes the present knowledge of prokinetics, with emphasis on
medications currently available, as well as drugs under clinical investigation,
including some agents in advanced clinical trials that are likely to be used in
the treatment of diabetic gastroparesis in the future. These include the ghrelin
agonists and newer 5-HT4 agonists devoid of cardiac side effects.


Investigators with authorship
NameInstitution
Irene SarosiekTexas Tech University Health Sciences Center

Complications